depositphotos/[email protected]
At a Glance
- CVS, Walgreens, Amazon Pharmacy and Publix participate in the nationwide Medicare GLP-1 program
- Novo Nordisk and Eli Lilly position Wegovy, Zepbound and Foundayo within the Bridge framework
- Program excludes patients with type 2 diabetes and ends December 31, 2027, creating pricing cliff
The arrival of the CMS’sMedicare GLP-1 Bridgeprogram has redrawn the map of drug pricing for weight management, setting a new, predictable monthly price point that is rippling across pharmacies, manufacturers, and care models. Since July 1, 2026, eligible Medicare Part D beneficiaries can access certain GLP-1 medications for a $50 copay through a short-term CMS demonstration that runs through December 31, 2027. Beyond widening access, the Bridge represents how these therapies are priced, processed, and supported.
The Bridge operates outside the traditional Part D coverage and payment flow, according to CMS. In turn, the Part D deductible doesn’t apply, no portion of the $50 copay counts toward a beneficiary’s true out-of-pocket (TrOOP), and low-income subsidies aren’t applied. Part D sponsors carry no risk for these drugs; instead, CMS uses a single central processor to manage prior authorization, claims adjudication, and pharmacy payments. In short, the program separates GLP-1 weight management prescriptions from the usual benefit mechanics and replaces them with a flat, federally administered price signal: $50 per month.
That predictability is already reshaping the market. Pharmacies are building services around the new price point, manufacturers are aligning access pathways, and digital care providers are integrating eligibility and prior authorization processes that match the program’s unified infrastructure
Retail’s rapid alignment
Major pharmacy chains have moved quickly to support the Bridge. CVS Pharmacy has committed to participation, pairing the $50 copay with clinical guidance and virtual access via MinuteClinic’s $49 visits. “Access is only part of the equation with GLP-1 medications. Patients also need support to stay on therapy and see results,” Sid Tenneti, Senior Vice President and Interim President, Pharmacy and Consumer Wellness at CVS Health,saidin a press release. CVS is also highlighting over-the-counter products to manage common side effects and offers additional affordability programs for those not eligible under Medicare, including manufacturer coupons and vouchers that can bring out-of-pocket costs as low as $25 for commercially insured patients or $149 for self-pay.
Walgreensis emphasizing pharmacist-led guidance at scale, noting the Bridge’s nationwide launch.Publix Pharmacyhas also joined, confirming it will fill qualifying prescriptions under the program
Amazon Pharmacy is leaning into logistics and administrative simplification, handling eligibility verification, prior authorization, and billing, with free home delivery and same-day delivery in thousands of cities. “We want to make sure nothing stands in the way—no confusing paperwork, no prior authorization delays, no waiting at a pharmacy counter,” said Tanvi Patel, vice president and general manager of Amazon Pharmacy, in apress release
Manufacturers embrace new access models
Novo Nordisk and Eli Lilly have positioned their GLP-1 portfolios squarely within the Bridge’s $50 copay structure. Wegovy (injection and pill) is now accessible to eligible Medicare patients, Novoannouncedin July
Meanwhile, Lilly’s Foundayo and Zepbound are likewise available through the program. “Lilly estimates that approximately 20 million Medicare patients may meet clinical criteria for obesity medicines, and starting July 1, eligible patients will be able to get Zepbound or Foundayo for $50 per month,”<a href="https://investor.lilly.com/news-releases/news-release-details/what-medicare-part-d-patients-need-know-about-accessing-foundayo” rel=”nofollow noopener” target=”_blank”>saidIlya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. Patients and clinicians now have a choice between a daily pill and a leading injectable, both integrated into the Bridge’s single-price framework, according to the company.
A Lilly spokesperson toldBioXconomy, “Lilly remains committed to working with CMS and other stakeholders to help people living with obesity have access to FDA-approved treatment options. We will continue to educate patients and their physicians about coverage options that can help patients access medications at the lowest possible out-of-pocket costs.”
When asked whether the Bridge program is forcing other GLP-1 manufacturers to adjust their pricing and rebate strategies, a Novo Nordisk spokesperson toldBioXconomy, “We can’t speak to other manufacturers’ pricing decisions. The Medicare GLP-1 Bridge operates within a Medicare-specific framework that is distinct from commercial insurance markets, so direct comparisons across channels can be challenging. Our focus is on supporting affordable access for eligible Medicare beneficiaries through the program.”
A comprehensive pathway
However, the Bridge program is not a free-for-all. Eligibility is tightly defined, and clinicians must assess patients, submit prior authorization through the central processor, and provide ongoing management. Enter Form Health, a digital healthcare provider specializing in obesity and cardiometabolic care. The company claims it’s one of the few digital healthcare providers with the clinical experience and infrastructure to support Medicare beneficiaries. The company serves as both a prescribing provider and comprehensive care coordinator within the Medicare GLP-1 Bridge Program.
Florencia Halperin, MD, chief medical officer at Form Health, calls the program “an important step in recognizing obesity as a chronic disease requiring evidence-based medical treatment,” while noting critical constraints: eligibility criteria based on BMI and comorbidities, exclusions for patients with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH with fibrosis
The new baseline
“There are questions about the program’s long-term sustainability, as it is currently authorized only through the end of 2027,” Halperin toldBioXconomy. “Even with those limitations, the Bridge Program sets a meaningful precedent by recognizing obesity as a chronic disease, not simply a weight management issue, and could help pave the way for broader Medicare coverage in the future
The Obesity Action Coalition sees progress—and a need for stability in the program. Commenting on the Bridge program, Joe Nadglowski, the organization’s president and CEO, said, “The Medicare GLP-1 Bridge program is a significant step forward for people living with obesity who have long faced barriers to access under Medicare.” However, the group stresses that “short-term access is not enough” and urges a pathway to comprehensive, lasting coverage
For now, the Bridge’s $50 copay anchors a new baseline in GLP-1 pricing for Medicare beneficiaries. Whether this temporary pricing architecture becomes the foundation for long-term policy remains unsettled. The December 31, 2027, end date creates a pricing cliff with significant financial implications. Patients who begin treatment under the $50 copay structure could face potential cost increases if the program isn’t extended or replaced with permanent coverage
Novo Nordisk spokesperson told us its current focus is on making the program successful for eligible patients and on generating experience to inform long-term approaches to obesity treatment access. “We continue to engage with CMS, policymakers, and other stakeholders on future access solutions. Any decisions regarding program design, coverage, or pricing beyond 2027 would depend on a variety of factors, and it would be premature to speculate at this time.”
Medicaid Drug Rebate Program Summit
|
Chicago, IL
Providing unparalleled access to the government regulators creating the rules, the industry leaders interpreting them and the manufacturer experts implementing them, the Medicaid Drug Rebate Program Summit gathers professionals to master complex regulatory guidelines to deliver compliant government pricing and reporting programs
RegisterLearn More
RegisterLearn More
Read more about:
Channel Management
